Man Group
KRTX

Man Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Man Group’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-35,000
Closed -$11.1M – 2322
2023
Q4 		$11.1M Buy
+35,000
New +$6.8M 0.03% 595
2023
Q3 		– Sell
-5,205
Closed -$979K – 891
2023
Q2 		$1.13M Buy
+5,205
New +$1.12M ﹤0.01% 1355
2023
Q1 		– Sell
-14,701
Closed -$2.89M – 2305
2022
Q4 		$2.89M Sell
14,701
-43,043
-75% -$9.23M 0.01% 1030
2022
Q3 		$13M Buy
+57,744
New +$11.7M 0.06% 388
2021
Q4 		– Sell
-7,372
Closed -$902K – 2170
2021
Q3 		$902K Sell
7,372
-10,345
-58% -$1.19M ﹤0.01% 1363
2021
Q2 		$2.02M Sell
17,717
-13,981
-44% -$1.63M 0.01% 1223
2021
Q1 		$3.81M Sell
31,698
-19,575
-38% -$2.22M 0.02% 822
2020
Q4 		$5.21M Buy
51,273
+3,105
+6% +$288K 0.02% 779
2020
Q3 		$3.72M Buy
48,168
+12,120
+34% +$1.03M 0.01% 953
2020
Q2 		$4.02M Buy
+36,048
New +$3.13M 0.02% 776

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Man Group's KRTX Position: Q1 2024 in Review

Man Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 35,000 shares — an estimated $11.1M sold.

Man Group first reported a position in KRTX in Q2 2020 and held it in 10 quarters. The position peaked at $13M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Man Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Man Group sold 35,000 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $11.1M.
  • Man Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
  • Man Group's Karuna Therapeutics, Inc. Common Stock position peaked at $13M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Man Group's 13F filing for Q1 2024, filed 15 May 2024.